X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs GLENMARK PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE GLENMARK PHARMA STRIDES PHARMA SCIENCE/
GLENMARK PHARMA
 
P/E (TTM) x 20.7 13.1 157.9% View Chart
P/BV x 0.9 2.3 37.9% View Chart
Dividend Yield % 0.5 0.4 122.0%  

Financials

 STRIDES PHARMA SCIENCE   GLENMARK PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
GLENMARK PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,147930 123.3%   
Low Rs642517 124.1%   
Sales per share (Unadj.) Rs317.2322.6 98.3%  
Earnings per share (Unadj.) Rs7.828.5 27.5%  
Cash flow per share (Unadj.) Rs25.139.2 63.9%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.3 80.9%  
Book value per share (Unadj.) Rs274.3183.0 149.9%  
Shares outstanding (eoy) m89.50282.17 31.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.2 125.7%   
Avg P/E ratio x114.025.4 448.9%  
P/CF ratio (eoy) x35.718.5 193.3%  
Price / Book Value ratio x3.34.0 82.5%  
Dividend payout %25.57.0 363.2%   
Avg Mkt Cap Rs m80,058204,206 39.2%   
No. of employees `0002.513.7 18.3%   
Total wages/salary Rs m4,34118,718 23.2%   
Avg. sales/employee Rs Th11,325.86,636.8 170.7%   
Avg. wages/employee Rs Th1,731.41,364.7 126.9%   
Avg. net profit/employee Rs Th280.1586.1 47.8%   
INCOME DATA
Net Sales Rs m28,39491,031 31.2%  
Other income Rs m941914 102.9%   
Total revenues Rs m29,33491,945 31.9%   
Gross profit Rs m3,96516,154 24.5%  
Depreciation Rs m1,5403,019 51.0%   
Interest Rs m1,9622,856 68.7%   
Profit before tax Rs m1,40311,193 12.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m973,155 3.1%   
Profit after tax Rs m7028,039 8.7%  
Gross profit margin %14.017.7 78.7%  
Effective tax rate %6.928.2 24.6%   
Net profit margin %2.58.8 28.0%  
BALANCE SHEET DATA
Current assets Rs m24,83669,887 35.5%   
Current liabilities Rs m18,99332,879 57.8%   
Net working cap to sales %20.640.7 50.6%  
Current ratio x1.32.1 61.5%  
Inventory Days Days7181 87.2%  
Debtors Days Days11393 121.3%  
Net fixed assets Rs m34,28928,892 118.7%   
Share capital Rs m895282 317.2%   
"Free" reserves Rs m23,65151,353 46.1%   
Net worth Rs m24,54651,635 47.5%   
Long term debt Rs m15,51341,418 37.5%   
Total assets Rs m65,437125,954 52.0%  
Interest coverage x1.74.9 34.9%   
Debt to equity ratio x0.60.8 78.8%  
Sales to assets ratio x0.40.7 60.0%   
Return on assets %4.18.6 47.1%  
Return on equity %2.915.6 18.4%  
Return on capital %6.915.1 45.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69736,317 43.2%   
Fx outflow Rs m7359,720 7.6%   
Net fx Rs m14,96226,598 56.3%   
CASH FLOW
From Operations Rs m1,87116,481 11.4%  
From Investments Rs m5,826-10,133 -57.5%  
From Financial Activity Rs m-10,157-4,685 216.8%  
Net Cashflow Rs m-2,6151,770 -147.7%  

Share Holding

Indian Promoters % 27.7 48.3 57.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 6.9 547.8%  
FIIs % 8.6 34.4 25.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 10.5 246.7%  
Shareholders   56,241 56,727 99.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   SHASUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare STRIDES PHARMA SCIENCE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

STRIDES PHARMA SCIENCE Plunges by 6%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

STRIDES PHARMA SCIENCE share price has plunged by 6% and its current market price is Rs 370. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 3.5%) and PFIZER (up 2.5%). The top losers is STRIDES PHARMA SCIENCE (down 5.6%)..

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati(Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance(The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 17, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - LUPIN COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS